Live attenuated tularemia vaccines: Recent developments and future goals

Vaccine

Volumn 31, Issue 35, 2013, Pages 3485-3491

  Marohn, Mark E ^a   Barry, Eileen M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Francisella tularensis; Live attenuated vaccines; LVS; Schu S4

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUCOSE TRANSPORTER; HEAT SHOCK PROTEIN; LIVE VACCINE; TULAREMIA VACCINE; VIRULENCE FACTOR;

BIOLOGICAL WARFARE; BIOSYNTHESIS; DEVELOPMENT; DISEASE COURSE; FOLATE METABOLISM; FRANCISELLA TULARENSIS; FUTUROLOGY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; IRON TRANSPORT; LETHAL DOSE; MEDICAL LITERATURE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES; VIRUS ATTENUATION; VIRUS MUTANT;

FRANCISELLA TULARENSIS; LIVE ATTENUATED VACCINES; LVS; SCHU S4;

BACTERIAL VACCINES; BIOLOGICAL WARFARE AGENTS; FRANCISELLA TULARENSIS; HUMANS; TULAREMIA; VACCINES, ATTENUATED;

EID: 84880737809     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.096     Document Type: Review

References (72)

1. Hornick R.B., Eigelsbach H.T. Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 1966, 30:532-538.
2. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007, 1105:1-29.
3. Oyston P.C., Sjostedt A., Titball R.W. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol 2004, 2:967-978.
4. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 1961, 107:702-714.
5. McCrumb F.R. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev 1961, 25:262-267.
6. Wayne Conlan J., Oyston P.C. Vaccines against Francisella tularensis. Ann N Y Acad Sci 2007, 1105:325-350.
7. Cross A.S., Calia F.M., Edelman R. From rabbits to humans: the contributions of Dr. Theodore E. Woodward to tularemia research. Clin Infect Dis 2007, 45(Suppl. 1):S61-S67.
8. Foshay L., Hesselbrock W.H., Wittenberg H.J., Rodenberg A.H. Vaccine prophylaxis against tularemia in man. Am J Public Health Nations Health 1942, 32:1131-1145.
9. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis 1977, 135:55-60.
10. El Sahly H.M., Atmar R.L., Patel S.M., Wells J.M., Cate T., Ho M., et al. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 2009, 27:4905-4911.
11. Pasetti M.F., Cuberos L., Horn T.L., Shearer J.D., Matthews S.J., House R.V., et al. An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine 2008, 26:1773-1785.
12. Fulop M., Manchee R., Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 1995, 13:1220-1225.
13. Sjostedt A., Sandstrom G., Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect Immun 1992, 60:2855-2862.
14. Fortier A.H., Slayter M.V., Ziemba R., Meltzer M.S., Nacy C.A. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 1991, 59:2922-2928.
15. Conlan J.W., Chen W., Shen H., Webb A., KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 2003, 34:239-248.
16. Pechous R., Celli J., Penoske R., Hayes S.F., Frank D.W., Zahrt T.C. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun 2006, 74:4452-4461.
17. Pechous R.D., McCarthy T.R., Mohapatra N.P., Soni S., Penoske R.M., Salzman N.H., et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One 2008, 3:e2487.
18. Lindgren H., Shen H., Zingmark C., Golovliov I., Conlan W., Sjostedt A. Resistance of Francisella tularensis strains against reactive nitrogen and oxygen species with special reference to the role of KatG. Infect Immun 2007, 75:1303-1309.
19. Santiago A.E., Cole L.E., Franco A., Vogel S.N., Levine M.M., Barry E.M. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine 2009, 27:2426-2436.
20. Jia Q., Lee B.Y., Bowen R., Dillon B.J., Som S.M., Horwitz M.A. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun 2010, 78:4341-4355.
21. Michell S.L., Dean R.E., Eyles J.E., Hartley M.G., Waters E., Prior J.L., et al. Deletion of the Bacillus anthracis capB homologue in Francisella tularensis subspecies tularensis generates an attenuated strain that protects mice against virulent tularaemia. J Med Microbiol 2010, 59:1275-1284.
22. Conlan J.W., Shen H., Golovliov I., Zingmark C., Oyston P.C., Chen W., et al. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 2010, 28:1824-1831.
23. Kim T.H., Pinkham J.T., Heninger S.J., Chalabaev S., Kasper D.L. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine. J Infect Dis 2012, 205:1056-1065.
24. Wayne Conlan J., Shen H., Kuolee R., Zhao X., Chen W. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-dependent mechanism. Vaccine 2005, 23:2477-2485.
25. Jayakar H.R., Parvathareddy J., Fitzpatrick E.A., Bina X.R., Bina J.E., Re F., et al. A galU mutant of Francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia. BMC Microbiol 2011, 11:179.
26. Marohn M.E., Santiago A.E., Shirey K.A., Lipsky M., Vogel S.N., Barry E.M. Members of the Francisella tularensis phagosomal transporter subfamily of major facilitator superfamily transporters are critical for pathogenesis. Infect Immun 2012, 80:2390-2401.
27. Sen B., Meeker A., Ramakrishnan G. The fslE homolog, FTL_0439 (fupA/B), mediates siderophore-dependent iron uptake in Francisella tularensis LVS. Infect Immun 2010, 78:4276-4285.
28. Russo B.C., Horzempa J., O'Dee D.M., Schmitt D.M., Brown M.J., Carlson P.E., et al. A Francisella tularensis locus required for spermine responsiveness is necessary for virulence. Infect Immun 2011, 79:3665-3676.
29. Ulland T.K., Janowski A.M., Buchan B.W., Faron M., Cassel S.L., Jones B.D., et al. Francisella tularensis LVS folate metabolism and pseudouridine synthase gene mutants modulate macrophage caspase-1 activation. Infect Immun 2013, 81:201-208.
30. Bakshi C.S., Malik M., Mahawar M., Kirimanjeswara G.S., Hazlett K.R., Palmer L.E., et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 2008, 26:5276-5288.
31. Twine S., Shen H., Harris G., Chen W., Sjostedt A., Ryden P., et al. BALB/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine 2012, 30:3634-3645.
32. Shen H., Harris G., Chen W., Sjostedt A., Ryden P., Conlan W. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One 2010, 5:e13349.
33. Ryden P., Twine S., Shen H., Harris G., Chen W., Sjostedt A., et al. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria. Mol Immunol 2012, 54:58-67.
34. Ireland P.M., LeButt H., Thomas R.M., Oyston P.C. A Francisella tularensis SCHU S4 mutant deficient in gamma-glutamyltransferase activity induces protective immunity: characterization of an attenuated vaccine candidate. Microbiology 2011, 157:3172-3179.
35. Rockx-Brouwer D., Chong A., Wehrly T.D., Child R., Crane D.D., Celli J., et al. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS One 2012, 7:e37752.
36. Qin A., Scott D.W., Thompson J.A., Mann B.J. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun 2009, 77:152-161.
37. Qin A., Scott D.W., Rabideau M.M., Moore E.A., Mann B.J. Requirement of the CXXC motif of novel Francisella infectivity potentiator protein B FipB, and FipA in virulence of F. tularensis subsp. tularensis. PLoS One 2011, 6:e24611.
38. Cole L.E., Santiago A., Barry E., Kang T.J., Shirey K.A., Roberts Z.J., et al. Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol 2008, 180:6885-6891.
39. West T.E., Pelletier M.R., Majure M.C., Lembo A., Hajjar A.M., Skerrett S.J. Inhalation of Francisella novicida Delta mglA causes replicative infection that elicits innate and adaptive responses but is not protective against invasive pneumonic tularemia. Microbes Infect 2008, 10:773-780.
40. Cole L.E., Elkins K.L., Michalek S.M., Qureshi N., Eaton L.J., Rallabhandi P., et al. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol 2006, 176:6888-6899.
41. Cole L.E., Shirey K.A., Barry E., Santiago A., Rallabhandi P., Elkins K.L., et al. Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages. Infect Immun 2007, 75:4127-4137.
42. Shirey K.A., Cole L.E., Keegan A.D., Vogel S.N. Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol 2008, 181:4159-4167.
43. Golovliov I., Kuoppa K., Sjostedt A., Tarnvik A., Sandstrom G. Cytokine expression in the liver of mice infected with a highly virulent strain of Francisella tularensis. FEMS Immunol Med Microbiol 1996, 13:239-244.
44. Golovliov I., Sandstrom G., Ericsson M., Sjostedt A., Tarnvik A. Cytokine expression in the liver during the early phase of murine tularemia. Infect Immun 1995, 63:534-538.
45. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999, 282:137-144.
46. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals 1997, 25:323-338.
47. Hiremath G.S., Omer S.B. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccines 2005, 1:30-36.
48. Valdespino-Gomez J.L., de Lourdes Garcia-Garcia M., Fernandez-de-Castro J., Henao-Restrepo A.M., Bennett J., Sepulveda-Amor J. Measles aerosol vaccination. Curr Top Microbiol Immunol 2006, 304:165-193.
49. Perry R.T., Plowe C.V., Koumare B., Bougoudogo F., Kotloff K.L., Losonsky G.A., et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ 1998, 76:63-71.
50. Ohtake S., Martin R.A., Saxena A., Lechuga-Ballesteros D., Santiago A.E., Barry E.M., et al. Formulation and stabilization of Francisella tularensis live vaccine strain. J Pharm Sci 2011, 100:3076-3087.
51. Rick Lyons C., Wu T.H. Animal models of Francisella tularensis infection. Ann N Y Acad Sci 2007, 1105:238-265.
52. Reed D.S., Smith L., Dunsmore T., Trichel A., Ortiz L.A., Cole K.S., et al. Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection. PLoS One 2011, 6:e24654.
53. Ray H.J., Chu P., Wu T.H., Lyons C.R., Murthy A.K., Guentzel M.N., et al. The Fischer 344 rat reflects human susceptibility to Francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One 2010, 5:e9952.
54. Wu T.H., Zsemlye J.L., Statom G.L., Hutt J.A., Schrader R.M., Scrymgeour A.A., et al. Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine 2009, 27:4684-4693.
55. Nelson M., Lever M.S., Dean R.E., Savage V.L., Salguero F.J., Pearce P.C., et al. Characterization of lethal inhalational infection with Francisella tularensis in the common marmoset (Callithrix jacchus). J Med Microbiol 2010, 59:1107-1113.
56. Nelson M., Lever M.S., Savage V.L., Salguero F.J., Pearce P.C., Stevens D.J., et al. Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus). Int J Exp Pathol 2009, 90:109-118.
57. Tempel R., Shirley R., McCarthy T., Zahrt T.C., Legasse A., Heffron F., et al. Tularemia vaccine trials in nonhuman primates. Abstracts of the 7th International Conference on Tularemia 2012, No. S12-4, p, 204.
58. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 1989, 11:440-451.
59. Crane D.D., Scott D.P., Bosio C.M. Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One 2012, 7:e33349.
60. Kurtz S.L., Foreman O., Bosio C.M., Anver M.R., Elkins K.L. Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun 2013, 81:585-597.
61. Keim P., Johansson A., Wagner D.M. Molecular epidemiology, evolution, and ecology of Francisella. Ann N Y Acad Sci 2007, 1105:30-66.
62. Staples J.E., Kubota K.A., Chalcraft L.G., Mead P.S., Petersen J.M. Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004. Emerg Infect Dis 2006, 12:1113-1118.
63. Twine S., Bystrom M., Chen W., Forsman M., Golovliov I., Johansson A., et al. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun 2005, 73:8345-8352.
64. Gil H., Platz G.J., Forestal C.A., Monfett M., Bakshi C.S., Sellati T.J., et al. Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc Natl Acad Sci USA 2006, 103:12897-12902.
65. Bakshi C.S., Malik M., Regan K., Melendez J.A., Metzger D.W., Pavlov V.M., et al. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol 2006, 188:6443-6448.
66. Raynaud C., Meibom K.L., Lety M.A., Dubail I., Candela T., Frapy E., et al. Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect Immun 2007, 75:536-541.
67. Sebastian S., Dillon S.T., Lynch J.G., Blalock L.T., Balon E., Lee K.T., et al. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun 2007, 75:2591-2602.
68. Li J., Ryder C., Mandal M., Ahmed F., Azadi P., Snyder D.S., et al. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 2007, 153:3141-3153.
69. Chakraborty S., Monfett M., Maier T.M., Benach J.L., Frank D.W., Thanassi D.G. Type IV pili in Francisella tularensis: roles of pilF and pilT in fiber assembly, host cell adherence, and virulence. Infect Immun 2008, 76:2852-2861.
70. Alkhuder K., Meibom K.L., Dubail I., Dupuis M., Charbit A. Glutathione provides a source of cysteine essential for intracellular multiplication of Francisella tularensis. PLoS Pathog 2009, 5:e1000284.
71. Qin A., Mann B.J. Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. BMC Microbiol 2006, 6:69.
72. Mann B.J., Santiago A.E., Qin A., Barry E.M. A highly protective type A-based live attenuated F. tularensis vaccine. Abstracts of the 7th International Conference on Tularemia 2012, No. S3-4, p. 31.